Demographic, epidemiological and clinical characteristics of a cohort of 49^ tuberculosis patients with COVID-19 disease
| Variable | Number/total number (%); Denominator corresponds to total number of patients for whom data are available |
| Age median [interquartile range] | 48 [32–69] |
| Male | 40/49 (81.6%) |
| Migrant status | 26/49 (53.1%) |
| Occupation | |
| Employed | 14/48 (29.2%) |
| Unemployed | 15/48 (31.3%) |
| Retired | 14/48 (29.2%) |
| Student | 5/48 (10.4%) |
| BCG vaccination | 19/30 (63.3%) |
| COPD/Asthma | 8/47 (17.0%) |
| Diabetes Mellitus | 8/49 (16.3%) |
| HIV infection | 6/48 (12.5%) |
| Renal failure | 5/49 (10.2%) |
| Liver disease | 7/49 (14.3%) |
| Alcohol abusea | 10/49 (20.4%) |
| Smokingb | 20/49 (40.8%) |
| Drug abuse | 4/47 (8.5%) |
| TUBERCULOSIS | |
| Previous history of TB | 13/46 (28.3%) |
| Site | |
| Pulmonary TB only | 36/49 (73.5%) |
| Extrapulmonary TB only | 1/49 (2.0%) |
| Pulmonary TB/ Extrapulmonary TB(>1 site possible) | 12/49 (24.5%) |
| Site of extrapulmonary TB | |
| Bone | 2/13 (15.4%) |
| Lymphadenitis | 2/13 (15.4%) |
| Pleural | 2/13 (15.4%) |
| Central Nervous System | 1/13 (7.7%) |
| Laryngeal | 1/13 (7.7%) |
| Gastrointestinal | 1/13 (7.7%) |
| Peritonitis+Lymphadenitis+Pleural+Bone | 1/13 (7.7%) |
| Genitourinary+Lymphadenitis | 1/13 (7.7%) |
| Central Nervous System+Lymphadenitis | 1/13 (7.7%) |
| Bone+Joint+Spondylodiscitis (T5-T11)+Paravertebral abscesses | 1/13 (7.7%) |
| Radiological involvement | |
| Unilateral cavitary lesions | 10/48 (20.8%) |
| Bilateral cavitary lesions | 13/48 (27.1%) |
| Bilateral infiltrates (no cavities) | 9/48 (18.8%) |
| Unilateral infiltrates | 16/48 (33.3%) |
| Microbiology | |
| Sputum culture confirmation | 22/49 (44.9%) (+8 sputum culture ongoing) |
| NAAT confirmation | 13/49 (26.5%) |
| Sputum smear positive | 9/49 (18.4%) |
| Not available | 5/49 (10.2%) |
| Drug resistance | |
| Resistant | 8/45 (17.8%) (4 MDR-TB) |
| Sensitive | 37/45 (82.2%) |
| Treatment outcome | |
| Cured | 6/49 (12.2%) |
| Completed | 1/49 (2.0%) |
| On treatment | 37/49 (75.5%) |
| Died# | 5/49 (10.2%) |
| Lost to follow-up | 0 |
| Failure | 0 |
| COVID-19 | |
| Symptoms | |
| Asymptomatic | 5/48 (10.4%) |
| Symptomatic | 43/48 (89.6%) |
| Imaging | |
| Typical (bilateral ground glass opacities) HRCT picture | 21/44 (47.7%) |
| Treatment outcome | |
| Resolved | 18/49 (36.7%) |
| Still on treatment | 25/49 (51.0%) |
| Died (at any date)# | 6/49 (12.3%) |
Abbreviations: SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; TB: tuberculosis; BCG: Bacillus Calmette-Guérin; COPD: chronic obstructive pulmonary disease; a: ≥14 drinks per week in men or ≥7 drinks per week in women; b: current or ex-smoker; NAAT: Nuclear Acid Amplification Test; MDR-TB: multidrug-resistant tuberculosis.
#According to the criteria for cohort analysis of treatment results the patients died during anti-TB treatment are 5 but the total number of deaths is 6 as one patient with post-TB treatment sequelae died after being cured for TB.